semaglutide oral cardiovascular indication 2025 news FDA Approves Rybelsus Oral Semaglutide for Cardiovascular Risk Reduction in Type 2 Diabetes: Insights from the SOUL Trial Clinical trial shows oral semaglutide

2019;366:l4898

Semaglutide is a drug that the FDA has approved for weight management under the brand name Wegovy

However, when you stop, you lose the biochemical changes it causes

Practical tips for people on 50 units Whether 50 units is your starting point, your current escalation step, or your maintenance dose, these practical considerations will help you get the most from your protocol

Longer term, it's the right thing to do." While Ozempic and Wegovy are known for inducing weight loss, Doustdar highlighted the drugs broader benefits for cardiovascular, kidney and liver health, most notably their ability to cure scarring in patients with fatty liver disease